(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.
Credit: Lilly The approval of Ebglyss, an interleukin-13 antagonist, was supported by data from 3 clinical trials. Ebglyss can be used with or without topical corticosteroids. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you